{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Liver Safety Required Actions and Follow up Assessments Section can be found in', 'Appendix 2.', '5.5.3.1.', 'Study Treatment Restart or Rechallenge', 'Study treatment restart or rechallenge after liver chemistry stopping criteria are met by', 'any subject participating in this study is not allowed.', '5.6.', 'Follow-up contact', 'A safety follow-up contact (Visit 6) should be conducted 7+3 days following the', 'completion of Visit 5 or the Early Withdrawal Visit, if applicable.', 'The following procedures will be performed:', 'AE/SAE assessment', 'COPD exacerbation assessment', 'Concomitant medication assessment limited to any medications used to treat a', 'COPD exacerbation or SAE (if applicable)', 'Pregnancy information (if applicable)', 'Subjects who have successfully completed all on-treatment randomized visits will be', 'discharged from the study upon completion of the safety follow-up contact.', '5.7.', 'Subject and Study Completion', 'A subject will be considered to have completed the study if he/she receives study', 'treatment at Visit 5 (Week 24) and completes the follow-up contact Visit 6.', \"The end of the study is defined as the last subject's last visit.\", '6.', 'STUDY TREATMENT', '6.1.', 'Investigational Product and Other Study Treatment', 'The term \"study treatment\\' is used throughout the protocol to describe any combination', 'of products received by the subject as per the protocol design. Study treatment may', 'therefore refer to the individual study treatments or the combination of those study', 'treatments.', 'The contents of the label will be in acaccordance with all applicable regulatory', 'requirements.', 'Under normal conditions of handling and administration, investigational product is not', 'expected to pose significant safety risks to site staff. Take adequate precautions to avoid', 'direct eye or skin contact and the generation of aerosols or mists. Notify the monitor of', 'any unintentional occupational exposure. A Material Safety Data Sheet (MSDS)', 'describing the occupational hazards and recommended handling precautions will be', '35']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'provided to site staff if required by local laws or will otherwise be available from GSK', 'upon request.', 'Investigational product must be stored in a secure area under the appropriate physical', 'conditions for the product. Access to and administration of the investigational product', 'will be limited to the investigator and authorised site staff. Investigational product must', 'be dispensed or administered only to subjects enrolled in the study and in accordance', 'with the protocol.', 'GlaxoSmithKline (GSK) will provide the study treatments for use in this study.', 'The following study medications will be used in this study:', 'UMEC/VI 62.5/ /25mcg administered via ELLIPTA', 'UMEC 62.5 mcg administered via ELLIPTA', 'Salmeterol 50 mcg administered via DISKUS', 'Placebo via ELLIPTA', 'Placebo via DISKUS', 'Subjects will be instructed to take one dose of medication each morning from the', 'ELLIPTA (one inhalation equals one dose), and one dose in the morning and one in the', 'evening from the DISKUS. Subject instructions and details on how to use the ELLIPTA', 'and DISKUS are provided in the study reference manual (SRM).', 'A description of the UMEC/VI investigational product administered via the ELLIPTA is', 'provided below in Table 1. The ELLIPTA will contain two, double-foil, laminate, blister', 'strips. The ELLIPTA will provide a total of 30 doses (60 blisters) and will deliver, when', 'actuated, the contents of a single blister simultaneously from each of the two blister', 'strips.', 'The DISKUS will provide a total of 60 doses and will deliver, when actuated, the', 'contents of a single blister.', 'A description of the UMEC investigational product administered via the ELLIPTA is', 'provided below in Table 2. A description of placebo inhalation powder via ELLIPTA is', 'shown in Table 3. A description of salmeterol 50mcg and placebo via DISKUS are', 'shown in Table 4 and Table 5 respectively.', 'Table 1', 'Description of UMEC/VI Inhalation Powder via ELLIPTA', 'Formulation', 'First strip', 'Second strip', 'Umeclidinium bromide blended with', 'Vilanterol trifenatate blended with', 'lactose monohydrate and', 'lactose monohydrate and magnesium', 'magnesium stearate\u00b9', 'stearate\u00b2', 'Dosage Form', 'ELLIPTA Inhaler with 30 doses (2 strips with 30 blisters per strip)', 'Unit Dose Strengths', '62.5 mcg', '25 mcg', 'Physical description', 'White powder', 'White powder', 'Route of Administration', 'Inhaled', '1.', 'Magnesium stearate 0.6% w/w of total drug product', '2.', 'Magnesium stearate 1.0% w/w of total drug product', '36']\n\n###\n\n", "completion": "END"}